Targets › GCDH
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.
Catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO(2) in the degradative pathway of L-lysine, L-hydroxylysine, and L-tryptophan metabolism. It uses electron transfer flavoprotein as its electron acceptor. (UniProt, Q92947)
Open in Phaseline: the race on GCDH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Vitalgen BioPharma | VGM-R02b rAAV9-mediated GCDH gene replacement therapy | GCDH | Phase 1 | Glutaric Acidemia Type I | Aug 2027 |
Glutaric Acidemia Type I (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.